Finally, the SYK inhibitor entospletinib also appears to be a promising drug with clinical activity for patients previously treated with BCR-pathway inhibitors; treatment was found to yield OS of 32.7% and PFS of 5.6 months when used in monotherapy in patients with R/R CLL who had been previously treated with ibrutinib, spebrutinib, idelalisib, or umbralisib [162]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.